Select Publications

Byrd JC et al. Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: Justification for risk-adapted therapy. J Clin Oncol 2006;24(3):437-43. Abstract

Hainsworth JD et al. Combination therapy with fludarabine and rituximab followed by alemtuzumab in the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: A phase 2 trial of the Minnie Pearl Cancer Research Network. Cancer 2008;112(6):1288-95. Abstract

Hillmen P et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol 2007;25(35):5616-23. Abstract

Hochhaus A et al. IRIS 6-year follow-up: Sustained survival and declining annual rate of transformation in patients with newly diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) treated with imatinib. Proc ASH 2007;Abstract 25.

Kantarjian H et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: A randomized phase 2 trial. Blood 2007;109(12):5143-50. Abstract

NCCN Clinical Practice Guidelines in Oncology^TM. Chronic Myelogenous Leukemia V.3.2008. http://www.nccn.org

Wendtner CM et al. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission — Experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia 2004;18(6):1093-101. Abstract

 

 

 

 

 

 

 

 

 

 

Table of Contents

Top of Page

Home

EDITOR
Neil Love, MD

INTERVIEWS
Susan M O’Brien, MD
- Select publications

Robert Z Orlowski, MD, PhD
- Select publications

David P Steensma, MD
- Select publications

David G Maloney, MD, PhD
- Select publications

Hematologic Oncology Update:
A CME Audio Series and Activity

Faculty Disclosures

Editor's Office